<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03273374</url>
  </required_header>
  <id_info>
    <org_study_id>3-2017-0171</org_study_id>
    <nct_id>NCT03273374</nct_id>
  </id_info>
  <brief_title>Intraoperative Radiation Therapy for Resectable Pancreatic Cancer</brief_title>
  <official_title>A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study is designed to investigate the efficacy of IORT for patients with&#xD;
      resectable pancreatic adenocarcinoma. The purpose of the study is to show the local&#xD;
      recurrence rate after surgical resection and IORT is superior to that of surgical resection&#xD;
      alone from the historical control. A total of 42 patients will be enrolled, and these&#xD;
      patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, followed by 6&#xD;
      cycles of adjuvant gemcitabine chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment outcomes of pancreatic cancer are poor even after surgical resection, thus patients&#xD;
      may receive adjuvant chemotherapy or chemoradiotherapy. Intraoperative radiotherapy (IORT)&#xD;
      with low energy (50 kV) x-ray allows delivery of a high dose radiation to the tumor bed&#xD;
      during surgery while effectively sparing adjacent critical organs. Another advantage of IORT&#xD;
      is that delivery of IORT does not interfere with the scheduled administration of adjuvant&#xD;
      chemotherapy or chemoradiotherapy. Here we investigate the efficacy of IORT for patients with&#xD;
      resectable pancreatic adenocarcinoma by comparing the local recurrence rate after surical&#xD;
      resection and IORT with that of surgical resection alone from the historical control. A total&#xD;
      of 42 patients will be enrolled in this phase II trial, and these patients will receive IORT&#xD;
      of 10 Gy at 5 millimeter depth of the tumor bed, followed by 6 cycles of adjuvant gemcitabine&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Anticipated">August 13, 2022</completion_date>
  <primary_completion_date type="Actual">August 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervention: intraoperative radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>Local recurrence rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Resectable Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>IORT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intraoperative radiation therapy (IORT)</intervention_name>
    <description>IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles</description>
    <arm_group_label>IORT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Pathologically confirmed pancreatic adenocarcinoma 2. Age ≥20 years 3. Performance&#xD;
             status ECOG 0-2 4. Patients must have resectable disease. In order to be resectable&#xD;
             the following criteria must be met:&#xD;
&#xD;
          -  Absence of distant metastases&#xD;
&#xD;
          -  Clear fat planes around the celiac axis, hepatic artery, and superior mesenteric&#xD;
             artery&#xD;
&#xD;
          -  Absence of direct involvement of inferior vena cava or aorta&#xD;
&#xD;
          -  Stage I-III disease per AJCC 7th edition 5. Laboratory data obtained ≤14 days prior to&#xD;
             registration on study, with adequate bone marrow and renal function defined as&#xD;
             follows:&#xD;
&#xD;
          -  Hemoglobin &gt;10 g/dL, Absolute Neutrophil Count (ANC) &gt;1,500/mm3, Platelets&#xD;
             &gt;100,000/mm3&#xD;
&#xD;
          -  Serum Cr &lt;1.4 mg/dL, BUN &lt;20 mg/dL 6. Ability to understand and the willingness to&#xD;
             sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who have received external beam radiotherapy in the abdominal area 2.&#xD;
             Defined treatment area which cannot be adequately covered by the radiation field as&#xD;
             defined by the radiation oncology treatment team 3. Patients who have received&#xD;
             neoadjuvant chemotherapy 4. Stage IV disease 5. Patients with distant metastases 6.&#xD;
             Current pregnancy or currently nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ik Jae Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 3, 2017</study_first_submitted>
  <study_first_submitted_qc>September 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Ik Jae Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

